Interleukin-23: A key cytokine in inflammatory diseases

Annals of Medicine

Volumn 43, Issue 7, 2011, Pages 503-511

  Duvallet, Emilie ^a,b   Semerano, Luca ^a,b   Assier, Eric ^a,b   Falgarone, Géraldine ^a,b   Boissier, Marie Christophe ^a,b  

^a UNIVERSITÉ PARIS 13   (France)

^b ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

Author keywords

Cytokines; Interleukin 23; Rheumatoid arthritis; Spondyloarthritis; T cells

Indexed keywords

CYTOKINE; GAMMA INTERFERON; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 1; INTERLEUKIN 12; INTERLEUKIN 17; INTERLEUKIN 17F; INTERLEUKIN 22; INTERLEUKIN 23; INTERLEUKIN 23 RECEPTOR; INTERLEUKIN 23P19; INTERLEUKIN 23P40; INTERLEUKIN 6; OSTEOCLAST DIFFERENTIATION FACTOR; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; USTEKINUMAB;

ANKYLOSING SPONDYLITIS; AUTOIMMUNITY; CROHN DISEASE; ENTERITIS; INFLAMMATORY DISEASE; INTERFERON PRODUCTION; OSTEOCLASTOGENESIS; PRIORITY JOURNAL; PSORIASIS; PSORIATIC ARTHRITIS; REVIEW; RHEUMATOID ARTHRITIS; TH1 CELL; TH17 CELL;

ANIMALS; DRUG DELIVERY SYSTEMS; DRUG DESIGN; HUMANS; INFLAMMATION; INTERLEUKIN-12; INTERLEUKIN-12 SUBUNIT P40; INTERLEUKIN-23; INTERLEUKIN-23 SUBUNIT P19; MACROPHAGES;

EID: 79960776307     PISSN: 07853890     EISSN: 13652060     Source Type: Journal    
DOI: 10.3109/07853890.2011.577093     Document Type: Review

References (62)

1. Le Goff B, Blanchard F, Berthelot JM, Heymann D, Maugars Y. Role for interleukin-6 in structural joint damage and systemic bone loss in rheumatoid arthritis. Joint Bone Spine. 2010;77:201-5.
2. Watford WT, Hissong BD, Bream JH, Kanno Y, Muul L, O Shea JJ. Signaling by IL-12 and IL-23 and the immunoregulatory roles of STAT4. Immunol Rev. 2004;202: 139-56. (Pubitemid 39576910)
3. Oppmann B, Lesley R, Blom B, Timans JC, Xu Y, Hunte B, et al. Novel p19 protein engages IL-12p40 to form a cytokine, IL-23, with biological activities similar as well as distinct from IL-12. Immunity. 2000;13:715-25.
4. Palmer G, Talabot-Ayer D, Lamacchia C, Toy D, Seemayer CA, Viatte S, et al. Inhibition of interleukin-33 signaling attenuates the severity of experimental arthritis. Arthritis Rheum. 2009;60:738-49.
5. Collison LW, Vignali DA. Interleukin-35: odd one out or part of the family? Immunol Rev. 2008;226:248-62.
6. Parham C, Chirica M, Timans J, Vaisberg E, Travis M, Cheung J, et al. A receptor for the heterodimeric cytokine IL-23 is composed of IL-12Rbeta1 and a novel cytokine receptor subunit, IL-23R. J Immunol. 2002;168:5699-708. (Pubitemid 34556153)
7. Cua DJ, Sherlock J, Chen Y, Murphy CA, Joyce B, Seymour B, et al. Interleukin-23 rather than interleukin-12 is the critical cytokine for autoimmune infl ammation of the brain. Nature. 2003;421:744-8. (Pubitemid 36227625)
8. Bastos KR, Marinho CR, Barboza R, Russo M, Alvarez JM, D Imperio Lima MR. What kind of message does IL-12/ IL-23 bring to macrophages and dendritic cells? Microbes Infect. 2004;6:630-6. (Pubitemid 38680607)
9. Kastelein RA, Hunter CA, Cua DJ. Discovery and biology of IL-23 and IL-27: related but functionally distinct regulators of infl ammation. Annu Rev Immunol. 2007;25:221-42. (Pubitemid 46697908)
10. Harrington LE, Hatton RD, Mangan PR, Turner H, Murphy TL, Murphy KM, et al. Interleukin 17-producing CD4- effector T cells develop via a lineage distinct from the T helper type 1 and 2 lineages. Nat Immunol. 2005;6:1123-32.
11. Boissier MC. Cell and cytokine imbalance in rheumatoid arthritis. Joint Bone Spine. 2010. DOI: 10.1016/j.jbspin. 2010.08.017.
12. Veldhoen M, Hocking RJ, Atkins CJ, Locksley RM, Stockinger B. TGFbeta in the context of an infl ammatory cytokine milieu supports de novo differentiation of IL-17-producing T cells. Immunity. 2006;24:179-89. (Pubitemid 43214587)
13. Manel N, Unutmaz D, Littman DR. The differentiation of human T(H)-17 cells requires transforming growth factorbeta and induction of the nuclear receptor RORgammat. Nat Immunol. 2008;9:641-9. (Pubitemid 351714729)
14. Ghoreschi K, Laurence A, Yang XP, Tato CM, McGeachy MJ, Konkel JE, et al. Generation of pathogenic T(H)17 cells in the absence of TGF-beta signalling. Nature. 2010; 467:967-71.
15. Buonocore S, Ahern PP, Uhlig HH, Ivanov II, Littman DR, Maloy KJ, et al. Innate lymphoid cells drive interleukin-23- dependent innate intestinal pathology. Nature. 2010;464: 1371-5.
16. Sutton CE, Lalor SJ, Sweeney CM, Brereton CF, Lavelle EC, Mills KH. Interleukin-1 and IL-23 induce innate IL-17 production from gammadelta T cells, amplifying Th17 responses and autoimmunity. Immunity. 2009;31:331-41.
17. Ito Y, Usui T, Kobayashi S, Iguchi-Hashimoto M, Ito H, Yoshitomi H, et al. Gamma/delta T cells are the predominant source of interleukin-17 in affected joints in collagen-induced arthritis, but not in rheumatoid arthritis. Arthritis Rheum. 2009;60:2294-303.
18. Cornelissen F, Mus AM, Asmawidjaja PS, van Hamburg JP, Tocker J, Lubberts E. Interleukin-23 is critical for full-blown expression of a non-autoimmune destructive arthritis and regulates interleukin-17A and RORgammat in gammadelta T cells. Arthritis Res Ther. 2009;11:R194.
19. Petermann F, Rothhammer V, Claussen MC, Haas JD, Blanco LR, Heink S, et al. Gammadelta T cells enhance autoimmunity by restraining regulatory T cell responses via an interleukin-23-dependent mechanism. Immunity. 2010;33: 351-63.
20. Hedrick MN, Lonsdorf AS, Shirakawa AK, Richard Lee CC, Liao F, Singh SP, et al. CCR6 is required for IL-23-induced psoriasis-like infl ammation in mice. J Clin Invest. 2009; 119:2317-29.
21. Ehlers S, Kaufmann SH. Infection, infl ammation, and chronic diseases: consequences of a modern lifestyle. Trends Immunol. 2010;31:184-90.
22. Uhlig HH, McKenzie BS, Hue S, Thompson C, Joyce- Shaikh B, Stepankova R, et al. Differential activity of IL-12 and IL-23 in mucosal and systemic innate immune pathology. Immunity. 2006;25:309-18.
23. Mannon PJ, Fuss IJ, Mayer L, Elson CO, Sandborn WJ, Present D, et al. Anti-interleukin-12 antibody for active Crohn s disease. N Engl J Med. 2004;351:2069-79. (Pubitemid 39482500)
24. Elson CO, Cong Y, Weaver CT, Schoeb TR, McClanahan TK, Fick RB, et al. Monoclonal anti-interleukin 23 reverses active colitis in a T cell-mediated model in mice. Gastroenterology. 2007;132:2359-70. (Pubitemid 46890867)
25. Duerr RH, Taylor KD, Brant SR, Rioux JD, Silverberg MS, Daly MJ, et al. A genome-wide association study identifies IL23R as an infl ammatory bowel disease gene. Science. 2006;314:1461-3. (Pubitemid 44871953)
26. Capon F, Di Meglio P, Szaub J, Prescott NJ, Dunster C, Baumber L, et al. Sequence variants in the genes for the interleukin-23 receptor (IL23R) and its ligand (IL12B) confer protection against psoriasis. Hum Genet. 2007; 122:201-6. (Pubitemid 47241785)
27. Town T, Bai F, Wang T, Kaplan AT, Qian F, Montgomery RR, et al. Toll-like receptor 7 mitigates lethal West Nile encephalitis via interleukin 23-dependent immune cell infiltration and homing. Immunity. 2009;30:242-53.
28. Stetson DB, Medzhitov R. T helper 17 cells get the NOD. Immunity. 2007;27:546-8. (Pubitemid 47615515)
29. T ato CM, Cua DJ. Reconciling id, ego, and superego within interleukin-23. Immunol Rev. 2008;226:103-11.
30. Fantini MC, Pallone F. Cytokines: from gut infl ammation to colorectal cancer. Curr Drug Targets. 2008;9:375-80. (Pubitemid 352025211)
31. Ljujic B, Radosavljevic G, Jovanovic I, Pavlovic S, Zdravkovic N, Milovanovic M, et al. Elevated serum level of IL-23 correlates with expression of VEGF in human colorectal carcinoma. Arch Med Res. 2010;41:182-9.
32. Sato K, Suematsu A, Okamoto K, Yamaguchi A, Morishita Y, Kadono Y, et al. Th17 functions as an osteoclastogenic helper T cell subset that links T cell activation and bone destruction. J Exp Med. 2006;203:2673-82. (Pubitemid 44833343)
33. Kyttaris VC, Zhang Z, Kuchroo VK, Oukka M, Tsokos GC. Cutting edge: IL-23 receptor deficiency prevents the development of lupus nephritis in C57BL/6-lpr/lpr mice. J Immunol. 2010;184:4605-9.
34. DeLay ML, Turner MJ, Klenk EI, Smith JA, Sowders DP, Colbert RA. HLA-B27 misfolding and the unfolded protein response augment interleukin-23 production and are associated with Th17 activation in transgenic rats. Arthritis Rheum. 2009;60:2633-43.
35. Ciccia F, Bombardieri M, Principato A, Giardina A, Tripodo C, Porcasi R, et al. Overexpression of interleukin-23, but not interleukin-17, as an immunologic signature of subclinical intestinal infl ammation in ankylosing spondylitis. Arthritis Rheum. 2009;60:955-65.
36. Keshav S. Paneth cells: leukocyte-like mediators of innate immunity in the intestine. J Leukoc Biol. 2006;80:500-8. (Pubitemid 44835783)
37. Melis L, Vandooren B, Kruithof E, Jacques P, De Vos M, Mielants H, et al. Systemic levels of IL-23 are strongly associated with disease activity in rheumatoid arthritis but not spondyloarthritis. Ann Rheum Dis. 2010;69:618-23.
38. Moura RA, Cascao R, Perpetuo I, Canhao H, Sousa E, Rosario AF, et al. Cytokine profile in serum and synovial fl uid of established rheumatoid arthritis patients (Poster). 7th International Congress on Autoimmunity; Ljubljana, Slovenia, 5-9 May 2010. PS11.
39. Kim HR, Kim HS, Park MK, Cho ML, Lee SH, Kim HY. The clinical role of IL-23p19 in patients with rheumatoid arthritis. Scand J Rheumatol. 2007;36:259-64.
40. Hillyer P, Larche MJ, Bowman EP, McClanahan TK, de Waal Malefyt R, Schewitz LP, et al. Investigating the role of the interleukin-23/-17A axis in rheumatoid arthritis. Rheumatology (Oxford). 2009;48:1581-9.
41. Kageyama Y, Kobayashi H, Kato N. Infl iximab treatment reduces the serum levels of interleukin-23 in patients with rheumatoid arthritis. Mod Rheumatol. 2009;19:657-62.
42. Rueda B, Orozco G, Raya E, Fernandez-Sueiro JL, Mulero J, Blanco FJ, et al. The IL23R Arg381Gln non-synonymous polymorphism confers susceptibility to ankylosing spondylitis. Ann Rheum Dis. 2008;67:1451-4.
43. Hollis-Moffatt JE, Merriman ME, Rodger RA, Rowley KA, Chapman PT, Dalbeth N, et al. Evidence for association of an interleukin 23 receptor variant independent of the R381Q variant with rheumatoid arthritis. Ann Rheum Dis. 2009; 68:1340-4.
44. Safrany E, Hobor R, Jakab L, Tarr T, Csongei V, Jaromi L, et al. Interleukin-23 receptor gene variants in Hungarian systemic lupus erythematosus patients. Infl amm Res. 2010; 59:159-64.
45. Kim HS, Kim I, Kim JO, Bae JS, Shin HD, Bae SC. No association between interleukin 23 receptor gene polymorphisms and systemic lupus erythematosus. Rheumatol Int. 2009;1:33-8.
46. Li Y, Liang WB, Li C, Gao LB, Zhou B, Wang YY, et al. The association between interleukin-23 receptor gene polymorphisms and systemic lupus erythematosus. DNA Cell Biol. 2010;29:79-82.
47. Leonardi CL, Kimball AB, Papp KA, Yeilding N, Guzzo C, Wang Y, et al. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1). Lancet. 2008; 371:1665-74. (Pubitemid 351671883)
48. Papp KA, Langley RG, Lebwohl M, Krueger GG, Szapary P, Yeilding N, et al. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, doubleblind, placebo-controlled trial (PHOENIX 2). Lancet. 2008;371:1675-84. (Pubitemid 351671884)
49. Krulig E, Gordon KB. Ustekinumab: an evidence-based review of its effectiveness in the treatment of psoriasis. Core Evid. 2010;5:11-22.
50. Liu J, Cao S, Herman LM, Ma X. Differential regulation of interleukin (IL)-12 p35 and p40 gene expression and interferon (IFN)-gamma-primed IL-12 production by IFN regulatory factor 1. J Exp Med. 2003;198:1265-76. (Pubitemid 37323391)
51. Griffiths CE, Strober BE, van de Kerkhof P, Ho V, Fidelus-Gort R, Yeilding N, et al. Comparison of ustekinumab and etanercept for moderate-to-severe psoriasis. N Engl J Med. 2010;362:118-28.
52. Sandborn WJ, Feagan BG, Fedorak RN, Scherl E, Fleisher MR, Katz S, et al. A randomized trial of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with moderate-to-severe Crohn s disease. Gastroenterology. 2008;135:1130-41.
53. Gottlieb A, Menter A, Mendelsohn A, Shen YK, Li S, Guzzo C, et al. Ustekinumab, a human interleukin 12/23 monoclonal antibody, for psoriatic arthritis: randomised, double-blind, placebo-controlled, crossover trial. Lancet. 2009;373:633-40.
54. Segal BM, Constantinescu CS, Raychaudhuri A, Kim L, Fidelus-Gort R, Kasper LH. Repeated subcutaneous injections of IL12/23 p40 neutralising antibody, ustekinumab, in patients with relapsing-remitting multiple sclerosis: a phase II, double-blind, placebo-controlled, randomised, doseranging study. Lancet Neurol. 2008;7:796-804.
55. Longbrake EE, Racke MK. Why did IL-12/IL-23 antibody therapy fail in multiple sclerosis? Expert Rev Neurother. 2009;9:319-21.
56. Elliott M, Benson J, Blank M, Brodmerkel C, Baker D, Sharples KR, et al. Ustekinumab: lessons learned from targeting interleukin-12/23p40 in immune-mediated diseases. Ann N Y Acad Sci. 2009;1182:97-110.
57. Lima XT, Abuabara K, Kimball AB, Lima HC. Briakinumab. Expert Opin Biol Ther. 2009;9:1107-13.
58. Gandhi M, Alwawi E, Gordon KB. Anti-p40 antibodies ustekinumab and briakinumab: blockade of interleukin-12 and interleukin-23 in the treatment of psoriasis. Semin Cutan Med Surg. 2010;29:48-52.
59. Duvallet E, Ratsimendresy R, Assier E, Delavallé e L, Bessis N, Zagury JF, et al. Active immunization against IL-23p19 improves collagen-induced-arthritis. Arthritis Rheum. 2009;10(Suppl):S1-2.
60. Zhang Y, Ma X. Triptolide inhibits IL-12/IL-23 expression in APCs via CCAAT/enhancer-binding protein alpha. J Immunol. 2010;184:3866-77.
61. Yang Y, Weiner J, Liu Y, Smith AJ, Huss DJ, Winger R, et al. T-bet is essential for encephalitogenicity of both Th1 and Th17 cells. J Exp Med. 2009;206:1549-64.
62. Looney RJ. B cell-targeted therapies for systemic lupus erythematosus: an update on clinical trial data. Drugs. 2010; 70:529-40.